P.A.W. Capital Corp continued to hold its stake in Abbott Laboratories (NYSE:ABT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,000 shares of the healthcare product maker’s stock at the end of the second quarter. P.A.W. Capital Corp’s holdings in Abbott Laboratories were worth $681,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Cypress Capital Management LLC WY increased its stake in shares of Abbott Laboratories by 37.9% during the first quarter. Cypress Capital Management LLC WY now owns 2,531 shares of the healthcare product maker’s stock worth $112,000 after acquiring an additional 696 shares during the period. Feltz Wealth PLAN Inc. acquired a new position in shares of Abbott Laboratories during the first quarter worth about $112,000. V Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the second quarter worth about $127,000. Atwood & Palmer Inc. increased its stake in shares of Abbott Laboratories by 157.5% during the first quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock worth $145,000 after acquiring an additional 2,000 shares during the period. Finally, Independent Portfolio Consultants Inc. increased its stake in shares of Abbott Laboratories by 9.3% during the first quarter. Independent Portfolio Consultants Inc. now owns 3,420 shares of the healthcare product maker’s stock worth $152,000 after acquiring an additional 292 shares during the period. Institutional investors and hedge funds own 71.66% of the company’s stock.

A number of research analysts have recently issued reports on ABT shares. TheStreet lowered shares of Abbott Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, May 18th. BidaskClub upgraded shares of Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Jefferies Group LLC reiterated a “buy” rating and set a $58.00 price target on shares of Abbott Laboratories in a research note on Thursday, June 29th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Friday, May 26th. Finally, Stifel Nicolaus boosted their price target on shares of Abbott Laboratories from $49.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $52.50.

In other news, insider Sharon J. Bracken sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the completion of the transaction, the insider now owns 28,806 shares in the company, valued at approximately $1,416,102.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brian J. Blaser sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $750,000.00. Following the transaction, the insider now owns 143,154 shares of the company’s stock, valued at approximately $7,157,700. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 218,150 shares of company stock valued at $10,811,179. Insiders own 0.76% of the company’s stock.

Shares of Abbott Laboratories (ABT) traded up 0.0474% during mid-day trading on Friday, hitting $51.7145. 3,129,026 shares of the company’s stock traded hands. The stock has a market cap of $89.85 billion, a P/E ratio of 72.4293 and a beta of 1.06. The stock has a 50 day moving average price of $49.96 and a 200-day moving average price of $46.88. Abbott Laboratories has a 1-year low of $37.38 and a 1-year high of $52.60.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The firm had revenue of $6.64 billion for the quarter, compared to analysts’ expectations of $6.63 billion. During the same quarter last year, the company earned $0.55 EPS. Abbott Laboratories’s quarterly revenue was up 24.5% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/abbott-laboratories-abt-stake-maintained-by-p-a-w-capital-corp.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.